<DOC>
	<DOCNO>NCT02598180</DOCNO>
	<brief_summary>Vergenix Flowable Gel indicate management acute chronic wound</brief_summary>
	<brief_title>VergenixTM Flowable Gel Patients With Lower Limb Ulcers</brief_title>
	<detailed_description>Vergenix™ Flowable Gel advance wound care device primarily make lyophilized Type I recombinant human Collagen ( rhCollagen ) . Vergenix Flowable Gel supply powder contain syringe hydrate saline , form gel . The Vergenix™ Flowable Gel provide scaffold cellular invasion capillary growth . A secondary dressing cover secure primary Vergenix™ Flowable Gel wound site follow final dressing application wrap wound surround area</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<criteria>Patient 18 year age old . 2 . Patient one follow difficulttotreat chronic ulcer low limb : 2.1 . Neuropathic low limb ulcer 2.2 . Venous low limb ulcer 2.3 . Post traumatic low limb ulcer 2.4 . Post operative low limb ulcer 3 . In case Neuropathic foot grade accord University Texas Classification 1A 4 . Wound area measurement range 120cm2 . 5 . Ulcer define grade ≥E granulometer scale . 6 . Willing adhere proper offload device ( load cast , heal shoe ) accord investigator recommendation . 7 . Female patient must negative serum pregnancy test screen willing able use medically acceptable method birth control declare abstain sexual intercourse , screen visit study termination visit surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) postmenopausal . Postmenopausal woman define woman menstruation cessation 12 consecutive month prior sign inform consent form . 8 . Ability willingness understand comply study procedure give write informed consent prior enrollment study . 1 . Acute ulcer 2 . Multiple Ulcers low limb . 3 . Clinical evidence infection soft tissue , joint and/or bone ( osteomyelitis ) present physical examination . 4 . The wound penetrate deep structure involve bone , tendon joint . 5 . Wound necrotic tissue . 6 . Wound sinus tract . 7 . HbA1c &gt; 12 . 8 . Patients skin disorder unrelated ulcer present adjacent target wound . 9 . Clinically significant arterial vascular disease AnkleBrachial Index ( ABI ) index &lt; 0.45 peripheral pulse palpable , flatted Pulse Volume Recording ( PVR ) case non palpable artery . 10 . Patient receiving , receive within one month prior enrollment treatment know impair wound healing , include limited : , immunosuppressive drug , cytotoxic agent , radiation therapy chemotherapy . 11 . Has active malignant disease kind . A patient , malignant disease past , treat currently diseasefree least 5 year , may consider study entry . 12 . Patients present significant metabolic comorbidity would preclude wound heal end stage renal failure , dialysis severe liver dysfunction . 13 . Clinically significant abnormality hematology blood chemistry lab test screen opinion investigator might interfere patient 's safety participation study . 14 . Known positive HIV . 15 . Known history significant medical disorder , investigator 's judgment contraindicate patient 's participation . 16 . Known hypersensitivity and/or allergy collagen . 17 . Drug alcohol abuse ( history ) . 18 . Patients participate clinical trial . 19 . Patients inability communicate well investigator staff ( i.e. , language problem , poor mental development impair cerebral function ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>